liquid pharmaceutical formulation for the sustained release of active ingredient (s), process for preparing this formulation, and process for preparing a powder derived from this formulation
"Pharmaceutical formulations for the prolonged release of active ingredient (s) as well as their especially therapeutic applications." The present invention relates to novel pharmaceutical formulations based on stable and fluid aqueous colloidal suspensions for the prolonged release of active principle (s), in particular protein (s), as well as the especially therapeutic applications of such formulations. The aim of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of active ingredient (s), allowing, after parenteral injection, to significantly increase the duration of in vivo release of a therapeutic protein by decreasing the peak concentration. active protein, which is, moreover, stable in conservation and, in addition, biocompatible, non-toxic, non-immunogenic and well tolerated locally. The formulation according to the invention is a low viscosity aqueous colloidal suspension of sub-micron water-soluble biodegradable polymer sub-micron particles and carrier of hydrophobic clusters (gh), such particles being non-covalently associated with at least one active ingredient (pa ) and forming a gelled deposit at the injection site, this gelling being caused by a protein present in the physiological medium."formulações farmacêuticas para a liberação prolongada de princípio(s) ativo(s), assim como suas aplicações especialmente terapêuticas". a presente invenção diz respeito a novas formulações farmacêuticas à base de suspensões coloidais aquosas estáveis e fluidas para a liberação prolongada de princípio (s) ativo(s), em particular protéico(s), assim como as aplicações, especialmente terapêuticas, dessas formulações. o objetivo da invenção é propor uma formulação farmacêutica fluida para a liberação prolongada de princípio(s) ativo(s), permitindo, após injeção por via parenteral, aumentar significativamente a duração de liberação in vivo de uma proteína terapêutica, diminuindo o pico de concentração plasmática da proteína ativa, e q
